Background

Most Neisseria meningitidis involved in invasive disease among American college students express serogroup B antigen. The Advisory Committee on Immunization Practices (ACIP) recommends healthcare providers (HCPs) share clinical decision making with patients to determine individual value of meningococcal serogroup B vaccination (MenB) rather than routinely recommend vaccination as with the meningococcal A,C,W,Y vaccine (MenACWY). This study examines the attitudes and practices of HCPs working in college student health centers (SHCs) regarding the recommendation and administration of MenB to students.

Methods

The study was conducted as an online and phone survey of SHC HCPs from a sample of colleges across the United States between May 2017 and July 2018. Items compared college SHC policies and practices for MenB to those for MenACWY. It also assessed perceived barriers to and facilitators of MenB delivery to students.

Results

Among the 147 respondents, almost 50% more reported their SHC stocked and administered MenACWY (54.1%) than MenB (37%) (p = .004). Almost five times as many colleges required their students receive MenACWY as MenB (53.5% vs. 10.5%, p < .001). A greater percentage requested students to submit records for MenACWY than MenB (77.3% vs. 46.9%, p < .001), and over three times as many tracked student-body coverage rates for MenACWY than MenB (55.6% vs. 15.8%, p < .001). Nearly three quarters of respondents estimated their college’s student body MenB coverage rate to be ≤ 10% or were unable to provide any estimate. Factors perceived by over half of the participants as moderate to extreme barriers to administering MenB included high upfront costs for SHCs to purchase and stock MenB (68.7%), and high out-of-pocket costs for students to receive it (82.8%).

Conclusions

A minority of college SHCs require, offer or track Men B vaccination on their campuses. Financial concerns are common barriers to SHCs’ stocking and administering MenB to students.

中文翻译：

---

高校校园内的血清B型脑膜炎球菌疫苗接种实践模式

背景

在美国大学生中，大多数与侵袭性疾病有关的脑膜炎奈瑟氏球菌都表达血清B群抗原。免疫实践咨询委员会（ACIP）建议医疗服务提供者（HCP）与患者共享临床决策以确定脑膜炎球菌B血清群疫苗（MenB）的个体价值，而不是像脑膜炎球菌A，C，W，Y疫苗那样常规推荐疫苗接种（MenACWY）。本研究探讨了在学生健康中心（SHC）中工作的HCP在向学生推荐和管理MenB方面的态度和做法。

方法

该研究是对2017年5月至2018年7月间来自美国各地大学的SHC HCP的在线和电话调查。项目比较了MenB与MenACWY的大学SHC政策和实践。它还评估了对向学生发送MenB的感知障碍和促进因素。

结果

在147名受访者中，报告说他们的SHC库存和使用MenACWY（54.1％）的比例比MenB（37％）高出近50％（p  = .004）。要求学生获得MenACWY的大学数量几乎是MenB的五倍（53.5％对10.5％，p  <.001）。要求学生提交MenACWY记录的比例高于MenB（77.3％比46.9％，p  <.001），并且跟踪的MenACWY学生身体覆盖率是MenB的三倍（55.6％比15.8％，p <.001）。近四分之三的受访者估计他们大学的学生身体MenB覆盖率≤10％或无法提供任何估计。超过一半的参与者认为，管理MenB的中度至极端障碍包括SHC购买和库存MenB的前期费用高（68.7％），以及学生获得MenB的自付费用高（82.8％）。

结论

少数大学SHC要求，提供或跟踪其校园中的男性B疫苗接种。财务上的担忧是SHC储存和管理MenB对学生的常见障碍。